Financing, Pricing, and Utilization of Pharmaceuticals in China

This paper examines the financing, pricing, and utilization of pharmaceuticals in China the pharmaceutical system as it has evolved, and some changes that would improve it in the context of the national health reform process. The present paper builds upon earlier critical reviews and other papers published in the series china health policy notes. The paper is divided into four parts. The first section provides an overview of the Chinese pharmaceutical market: how the sector has grown; China's position in the global market; and size, composition, and trends in the domestic market. The second section examines the evolution and status of China's system of essential medicines, an area emphasized in the government's health reform plan announced in April 2009. It shows how the use of essential medicines has evolved over the two decades since the idea was formally adopted, and discusses why practice has fallen far short of the ideal. The third section looks at the issue that dominates today's debate: managing high pharmaceutical costs. It reviews the components of drug pricing, underscoring the argument that there is considerable scope for reducing prices. It looks at government attempts to control drug prices, and suggests why they did not succeed. Finally, the fourth section suggests measures to re-chart the path to reform.

Bibliographic Details

Main Author:	World Bank
Format:	Policy Note biblioteca
Language:	English en_US
Published:	Washington, DC 2010
Subjects:	ACCESS TO PHARMACEUTICALS, ACCOUNTABILITY, ACCOUNTING, ACTIVE INGREDIENTS, ADVERTISING, AGGRESSIVE, AGING, ANALGESICS, ANESTHESIA, ANTIBIOTICS, AVERAGE PRICE, BENCHMARKS, BIDDING, BLOOD PRODUCTS, BRAND, BRAND NAME, BRAND NAME DRUGS, BRAND NAMES, BUDGETING, CAPACITY BUILDING, CENTER FOR HEALTH, CHINESE POPULATION, CHRONIC CONDITIONS, CHRONIC DISEASES, CITIZENS, CLINICAL GUIDELINES, CLINICAL TRIALS, COMMUNITY HEALTH, COMMUNITY PHARMACIES, COMPETITIVE BIDDING, COOPERATIVE MEDICAL INSURANCE, CORRUPTION, DEVELOPING COUNTRIES, DIABETES, DIFFERENTIAL PRICING, DISSEMINATION, DOMESTIC EXPENDITURES, DOMESTIC MANUFACTURERS, DOMESTIC MARKET, DONATIONS, DOSAGES, DRUG PRESCRIBING, DRUG PRICES, DRUGS, ECONOMIC TRANSITION, ESSENTIAL DRUGS, ESSENTIAL MEDICINES, EXPENDITURE, EXPENDITURES, EXPORT MARKET, FAMILIES, FAMILY PLANNING, FEES FOR SERVICES, GENERIC DRUGS, GMP, GOOD MANUFACTURING PRACTICES, HEALTH CARE, HEALTH CENTERS, HEALTH FACILITIES, HEALTH INSURANCE, HEALTH POLICY, HEALTH REFORM, HEALTH SECTOR, HEALTH SERVICES, HEALTH SYSTEM, HOSPITAL, HOSPITAL PHARMACIES, HOSPITALS, HYPERTENSION, ILLNESS, IMMUNIZATION, IMPORTED DRUGS, INFORMATION SYSTEM, INSURANCE SCHEMES, IRRATIONAL USE, LARGE CITIES, LOCAL GOVERNMENTS, MARKET PRICE, MARKET PRICES, MARKET SHARE, MARKETING, MARKETPLACE, MEDICAL EDUCATION, MEDICAL INSURANCE, MEDICAL SERVICES, MEDICATION, MEDICINE, MEDICINES, MENTAL HEALTH, MINISTRY OF HEALTH, MONOPOLIES, NATIONAL DEVELOPMENT, NATIONAL DRUG, NATIONAL ESSENTIAL DRUG LISTS, NATIONAL LEVEL, NATIONAL POLICY, NDP, NURSES, NUTRITION, PACKAGING, PATENTS, PATIENT, PATIENTS, PHARMACEUTICAL, PHARMACEUTICAL COMPANIES, PHARMACEUTICAL COST CONTAINMENT, PHARMACEUTICAL COSTS, PHARMACEUTICAL DISTRIBUTION, PHARMACEUTICAL EXPENDITURE, PHARMACEUTICAL INDUSTRY, PHARMACEUTICAL LAW, PHARMACEUTICAL MANUFACTURERS, PHARMACEUTICAL MANUFACTURING, PHARMACEUTICAL PRICES, PHARMACEUTICAL PRICING, PHARMACEUTICAL PRODUCTS, PHARMACEUTICAL QUALITY, PHARMACEUTICAL REFORM, PHARMACEUTICAL SECTOR, PHARMACEUTICAL SUPPLY, PHARMACEUTICALS, PHARMACOECONOMIC EVALUATION, PHARMACY, PHYSICIANS, POOLED PROCUREMENT, POOR FAMILIES, PRESCRIPTIONS, PREVENTIVE HEALTH CARE, PRICE ADJUSTMENTS, PRICE CAPS, PRICE CHANGES, PRICE CONTROL, PRICE CONTROLS, PRICE INCREASES, PRICE LIST, PRICE REGULATION, PRICE SETTING, PRICING POLICIES, PRICING POLICY, PROCUREMENT, PUBLIC DEBATE, PUBLIC HEALTH, PUBLIC HEALTH SERVICES, PUBLIC HEARINGS, PUBLIC HOSPITALS, PURCHASING, QUALITY ASSURANCE, QUALITY CONTROL, QUALITY OF LIFE, REBATES, RETAIL, RETAIL PRICE, RETAIL PRICES, RURAL AREAS, SALE, SALES, SCIENTIFIC EVIDENCE, SOCIAL CONSEQUENCES, SOCIAL HEALTH INSURANCE, SOCIAL POLICY, SOCIAL SECURITY, SOCIAL WELFARE, SPECIFIC INCENTIVES, STATE PLANNING, SUBSTITUTE, SUPPLY CHAIN, SURGERY, SURPLUS, TENDERING, TRADITIONAL MEDICINES, TREATMENT GUIDELINES, URBAN AREAS, URBAN CENTERS, URBAN COMMUNITY, VACCINES, WHOLESALE PRICE, WORKERS, WORLD HEALTH ORGANIZATION,
Online Access:	http://documents.worldbank.org/curated/en/933311468216270181/Main-report https://hdl.handle.net/10986/27598
Tags:	Add Tag No Tags, Be the first to tag this record!